China granted Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) a marketing license for its cobamamide capsules for anemia, according to a Friday filing with the Hong Kong bourse.
Shares closed 1% higher during trading on Monday.
The drug is indicated for conditions such as megaloblastic and nutritional anemia, as well as anemia during pregnancy, polyneuritis, radiculitis, trigeminal neuralgia, sciatica, and nerve palsy, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.